Pr\u016fkopnick\u00e1 l\u00e9\u010dba zn\u00e1m\u00e1 jako terapie chim\u00e9rick\u00fdmi receptory antigenu T (CAR T-bun\u011b\u010dn\u00e1 terapie) se uk\u00e1zala jako v\u00fdznamn\u00fd miln\u00edk v boji proti rakovin\u011b. Tento inovativn\u00ed p\u0159\u00edstup zahrnuje genetickou modifikaci vlastn\u00edch imunitn\u00edch bun\u011bk pacienta, aby c\u00edlily a ni\u010dily rakovinn\u00e9 bu\u0148ky.<\/p>\n\n
Dimas Padilla, \u010dlov\u011bk, kter\u00fd p\u0159e\u017eil non-Hodgkin\u016fv lymfom, \u010delil ponur\u00e9 progn\u00f3ze pot\u00e9, co se jeho rakovina vr\u00e1tila pot\u0159et\u00ed. Nad\u011bji v\u0161ak na\u0161el v CAR T-bun\u011b\u010dn\u00e9 terapii. Pot\u00e9, co mu byly odebr\u00e1ny T-bu\u0148ky, vlo\u017eili do nich technici nov\u00fd gen, kter\u00fd jim umo\u017enil produkovat nov\u00e9 povrchov\u00e9 receptory, kter\u00e9 by vyhled\u00e1valy a v\u00e1zaly se na specifick\u00e9 proteiny na jeho lymfomov\u00fdch bu\u0148k\u00e1ch.<\/p>\n\n
B\u011bhem n\u011bkolika t\u00fddn\u016f po p\u0159ijet\u00ed modifikovan\u00fdch T-bun\u011bk se Padill\u016fv n\u00e1dor na krku v\u00fdrazn\u011b zmen\u0161il. O rok pozd\u011bji byl st\u00e1le bez rakoviny a slavil sv\u00e9 znovu nabyt\u00e9 zdrav\u00ed se svou rodinou. Klinick\u00e9 hodnocen\u00ed, kter\u00e9ho se Padilla z\u00fa\u010dastnil, prok\u00e1zalo pozoruhodn\u00fd \u00fasp\u011bch, p\u0159i\u010dem\u017e p\u0159ibli\u017en\u011b polovina pacient\u016f dos\u00e1hla \u00fapln\u00e9 remise. Tento \u00fasp\u011bch je v\u00fdrazn\u011b vy\u0161\u0161\u00ed ne\u017e u tradi\u010dn\u00edch l\u00e9\u010debn\u00fdch postup\u016f.<\/p>\n\n
\u00da\u0159ad pro kontrolu potravin a l\u00e9\u010div (FDA) uznal potenci\u00e1l CAR T-bun\u011b\u010dn\u00e9 terapie a schv\u00e1lil verzi l\u00e9\u010dby nazvanou Yescarta pro ur\u010dit\u00e9 typy B-bun\u011b\u010dn\u00e9ho lymfomu. To znamen\u00e1 teprve druhou genovou terapii schv\u00e1lenou FDA pro l\u00e9\u010dbu rakoviny.<\/p>\n\n
CAR T-bun\u011b\u010dn\u00e1 terapie funguje tak, \u017ee geneticky modifikuje T-bu\u0148ky pacienta tak, aby exprimovaly chim\u00e9rick\u00fd antigenn\u00ed receptor (CAR). Tento receptor je navr\u017een tak, aby rozpoznal a nav\u00e1zal se na specifick\u00fd proteinov\u00fd c\u00edl na povrchu rakovinn\u00fdch bun\u011bk. Jakmile jsou v\u00e1z\u00e1ny, T-bu\u0148ky se aktivuj\u00ed a zni\u010d\u00ed rakovinn\u00e9 bu\u0148ky.<\/p>\n\n
P\u0159esto\u017ee CAR T-bun\u011b\u010dn\u00e1 terapie uk\u00e1zala velk\u00fd p\u0159\u00edslib, nese s sebou ur\u010dit\u00e1 rizika a vedlej\u0161\u00ed \u00fa\u010dinky. L\u00e9\u010dba je v sou\u010dasn\u00e9 dob\u011b dostupn\u00e1 pouze pacient\u016fm, u kter\u00fdch selhaly alespo\u0148 dv\u011b jin\u00e9 formy terapie. Imunoterapie, v\u010detn\u011b CAR T-bun\u011b\u010dn\u00e9 terapie, m\u016f\u017ee zp\u016fsobit nebezpe\u010dn\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky, jako je neurologick\u00e1 toxicita a syndrom uvol\u0148ov\u00e1n\u00ed cytokin\u016f (CRS). CRS je \u017eivot ohro\u017euj\u00edc\u00ed stav, kter\u00fd m\u016f\u017ee nastat, kdy\u017e jsou cytokiny uvol\u0148ov\u00e1ny aktivn\u00edmi b\u00edl\u00fdmi krvinkami, co\u017e vede k z\u00e1n\u011btu.<\/p>\n\n
Navzdory potenci\u00e1ln\u00edm rizik\u016fm mohou p\u0159\u00ednosy CAR T-bun\u011b\u010dn\u00e9 terapie p\u0159eva\u017eovat nad nep\u0159\u00edjemnostmi u pacient\u016f s pokro\u010dilou rakovinou a omezen\u00fdmi mo\u017enostmi l\u00e9\u010dby. Padilla zaznamenal vedlej\u0161\u00ed \u00fa\u010dinky, jako hore\u010dku a do\u010dasnou ztr\u00e1tu pam\u011bti, nakonec se v\u0161ak zotavil a vr\u00e1til se k norm\u00e1ln\u00edmu zdrav\u00ed.<\/p>\n\n
CAR T-bun\u011b\u010dn\u00e1 terapie m\u00e1 potenci\u00e1l zm\u011bnit l\u00e9\u010dbu rakoviny. Nab\u00edz\u00ed novou nad\u011bji pacient\u016fm s d\u0159\u00edve nevyl\u00e9\u010diteln\u00fdmi formami rakoviny. Je v\u0161ak zapot\u0159eb\u00ed dal\u0161\u00ed v\u00fdzkum, aby se zlep\u0161ila \u00fa\u010dinnost a bezpe\u010dnost l\u00e9\u010dby. Etick\u00e9 aspekty mus\u00ed b\u00fdt tak\u00e9 br\u00e1ny v \u00favahu, proto\u017ee se CAR T-bun\u011b\u010dn\u00e1 terapie st\u00e1v\u00e1 roz\u0161\u00ed\u0159en\u011bj\u0161\u00ed.<\/p>\n\n
Dlouhodob\u00e9 v\u00fdhody a v\u00fdzvy CAR T-bun\u011b\u010dn\u00e9 terapie jsou st\u00e1le zkoum\u00e1ny. V\u00fdzkumn\u00edci zkoumaj\u00ed, jak l\u00e9\u010dbu zefektivnit a u\u010dinit trvalej\u0161\u00ed. Tak\u00e9 zkoumaj\u00ed zp\u016fsoby, jak sn\u00ed\u017eit vedlej\u0161\u00ed \u00fa\u010dinky a zlep\u0161it zotaven\u00ed pacient\u016f.<\/p>\n\n
CAR T-bun\u011b\u010dn\u00e1 terapie p\u0159edstavuje v\u00fdznamn\u00fd krok sm\u011brem k personalizovan\u00e9 l\u00e9\u010db\u011b rakoviny. L\u00e9ka\u0159i mohou \u00fapravou l\u00e9\u010dby na specifick\u00e9 rakovinn\u00e9 bu\u0148ky pacienta potenci\u00e1ln\u011b dos\u00e1hnout \u00fa\u010dinn\u011bj\u0161\u00edch a c\u00edlen\u011bj\u0161\u00edch v\u00fdsledk\u016f. Sou\u010dasn\u00fd v\u00fdzkum se zam\u011b\u0159uje na roz\u0161\u00ed\u0159en\u00ed vyu\u017eit\u00ed CAR T-bun\u011b\u010dn\u00e9 terapie na \u0161ir\u0161\u00ed \u0161k\u00e1lu typ\u016f rakoviny.<\/p>\n\n
<\/code><\/pre>","protected":false},"excerpt":{"rendered":"Inovativn\u00ed \u00fatok proti rakovin\u011b zalo\u017een\u00fd na DNA ukazuje slibn\u00e9 v\u00fdsledky Miln\u00edk v genov\u00e9 terapii Pr\u016fkopnick\u00e1 l\u00e9\u010dba zn\u00e1m\u00e1 jako terapie chim\u00e9rick\u00fdmi receptory antigenu T (CAR T-bun\u011b\u010dn\u00e1 terapie) se uk\u00e1zala jako v\u00fdznamn\u00fd…<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1763],"tags":[15186,3368,3369,358,22778],"class_list":["post-17300","post","type-post","status-publish","format-standard","hentry","category-biotechnology","tag-gene-therapy","tag-immunotherapy","tag-cancer-treatment","tag-medical-innovation","tag-car-t-cell-therapy"],"_links":{"self":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts\/17300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/comments?post=17300"}],"version-history":[{"count":1,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts\/17300\/revisions"}],"predecessor-version":[{"id":17301,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/posts\/17300\/revisions\/17301"}],"wp:attachment":[{"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/media?parent=17300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/categories?post=17300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lifescienceart.com\/cs\/wp-json\/wp\/v2\/tags?post=17300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}